Compare Abbott Laboratories (ABT) vs A O Smith Corp (AOS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs A O Smith Corp — how do they compare? Abbott Laboratories trades at $95.55 (market cap $166.94B), while A O Smith Corp trades at $59.78 (market cap $8.45B). The key difference: Abbott Laboratories is far larger — about 19.8× A O Smith Corp's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | AOS | |
|---|---|---|
Market Cap | $166.94B | $8.45B |
Sector | Health | Industrials |
52-Week High | $136.62 | $80.47 |
52-Week Low | $82.57 | $55.78 |
Enterprise Value | $193.69B | $8.90B |
Dividend Yield | 2.63% | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
A.O. Smith (AOS) trades at $61.31, down 2.25% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported a Q1 2026 earnings miss ($0.85 actual vs. $0.94 expected) but maintains strong profitability with a 13.84% net margin and 28.27% ROE. Recent leadership changes include CEO Stephen Shafer becoming chairman as of July 1, 2026 (PRNewswire, June 22, 2026).
The stock shows mixed signals: solid fundamentals and a $68 consensus price target suggest upside, but recent earnings weakness and repeated Zacks Strong Sell ratings (June 18, 2026) indicate near-term headwinds. Investors face risks from China market softness and competitive pressures, though cash flow stability and dividend payments provide support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About A O Smith Corp
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.
Read more on AOS →
